Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Promising agents in AML: menin inhibitors & magrolimab in TP53-mutated AML

Eytan Stein • 28 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia Antibodies Magrolimab

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares his excitement for the development of menin inhibitors in acute myeloid leukemia (AML) and for upcoming data on the efficacy of magrolimab in TP53-mutated AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eytan Stein

1:27
The role of menin inhibitors in the treatment of HR-MDS and AML
Eytan Stein • 5 May 2023
1:09
Differences and similarities between MDS and AML & how this can inform treatment decisions
Eytan Stein • 5 May 2023
2:53
The prognostic impact of IDH mutations and the role of IDH inhibitors in MDS
Eytan Stein • 5 May 2023
1:37
A Phase II trial evaluating E7820 in patients with AML with splicing factor mutations
Eytan Stein • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals